SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales is pegged at Rs. 573.49 millions for the June 2025 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 765.36 millions during the year-ago period.The Net Loss for the quarter ended June 2025 is Rs. -137.27 millions as compared to Net Profit of Rs. 26.86 millions of corresponding quarter ended June 2024Operating profit Margin for the quarter ended June 2025 slipped to -45.02% as compared to 82.22% of corresponding quarter ended June 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 573.49 765.36 -25.07 573.49 765.36 -25.07 3182.30 3685.95 -13.66
Other Income 0.00 0.20 -100.00 0.00 0.20 -100.00 4.98 0.98 408.16
PBIDT -45.02 82.22 -154.76 -45.02 82.22 -154.76 363.00 174.92 107.52
Interest 40.44 37.63 7.47 40.44 37.63 7.47 149.33 139.17 7.30
PBDT -85.46 44.59 -291.66 -85.46 44.59 -291.66 213.67 35.75 497.68
Depreciation 43.81 38.73 13.12 43.81 38.73 13.12 163.78 146.32 11.93
PBT -129.27 5.86 -2305.97 -129.27 5.86 -2305.97 49.89 -110.57 -145.12
TAX 8.00 -21.00 -138.10 8.00 -21.00 -138.10 -19.35 -20.08 -3.64
Deferred Tax 8.00 -21.00 -138.10 8.00 -21.00 -138.10 -20.18 -22.00 -8.27
PAT -137.27 26.86 -611.06 -137.27 26.86 -611.06 69.24 -90.49 -176.52
Equity 158.28 158.28 0.00 158.28 158.28 0.00 158.28 158.28 0.00
PBIDTM(%) -7.85 10.74 -173.07 -7.85 10.74 -173.07 11.41 4.75 140.37

Mangalam Drugs&Org. Share Price

30.56 -0.62 (-1.99%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×